Factive launch by year-end
Executive Summary
GeneSoft will launch Factive (geminfloxacin) in late 2003 after FDA approval April 4 for mild to moderate community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The indication follows FDA's Anti-Infective Drugs Advisory Committee recommendation (1"The Pink Sheet" March 10, p. 11)...